HYPERFINE, INC.

Analyst Reco. Hyperfine, Inc.

Equities

HYPR

US44916K1060

Delayed Nasdaq Other stock markets 10:48:09 2024-04-29 am EDT			5-day change	1st Jan Change
0.832 ^USD	-1.54%		-2.12%	-25.71%

Apr. 17	Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study	CI
Mar. 22	Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating	Mar. 22	MT
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating	Mar. 22	MT
Jefferies Starts Hyperfine With Hold Rating	Nov. 30	MT
B. Riley Lifts Hyperfine's Price Target to $3.50 From $2.50 After Higher-Than-Expected Q2 Results, Keeps Buy Rating	23-08-15	MT
B. Riley Adjusts Price Target on Hyperfine to $2.50 From $3.50 After Softer-Than-Expected Q4 Results, 2023 Guidance; Keeps Buy Rating	23-03-22	MT
B. Riley Securities Initiates Hyperfine at Buy with $3.50 Price Target	22-10-04	MT
Wells Fargo Lowers Hyperfine to Equalweight From Overweight, Price Target to $2.40 From $8	22-08-11	MT
Evercore ISI Adjusts Hyperfine's Price Target to $5.50 From $7, Maintains Outperform Rating	22-07-05	MT
Evercore ISI Starts Hyperfine at Outperform With $7 Price Target	22-05-31	MT
Wells Fargo Initiates Hyperfine at Overweight With $8 Price Target	22-04-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer